Clinical Trial Update: Efficacy of Radium 223 in Radioactive Iodine Refractory Bone Metastases From Differentiated Thyroid Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating efficacy of Radium 223 in radioactive iodine-refractory bone metastases from differentiated thyroid cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Differentiated Thyroid Cancer
• Thyroid Cancer

Drugs mentioned

• Radium-223 (radium-223 dichloride)

Snippet

Sponsor: Gustave Roussy, Cancer Campus, Grand Paris | Conditions: Thyroid Cancer | Phase 2 | Status: COMPLETED